Senhwa Biosciences, Inc.

About Us
News
- Latest News
- Media coverage
Platform
- Pipeline
- CX-5461
- CX-4945
Clinical Trial
Investor Relations
Contact Us
- Contact Us
- Benefits

EN CH

AboutÂ Us

BringingÂ HopeÂ ToÂ Life

HOME
ABOUT US
MILESTONES

Company Profile
Milestones
Company Organizations
Management team
Consultants
Global Office

2012

2013

2014

2015

2016

2017

2018

Nov.	Senhwa Biosciences, Inc. begins operation on Nov. 16, 2012. Senhwa had raised NTD$ 339 million in its first round of funding

Apr.	Senhwa signed an Asset Purchase and Sale Agreement with the American biotechnology company. Senhwa’s US subsidiary is foundedin April, 2013. CX-5461: A phase I clinical trial in hematologic malignancies is initiated with Peter MacCallum Cancer Center (PMCC) in Australia.
Sept.	Senhwa completed its NTD$ 25 million fundraising
Nov.	Funded by New Taipei City Government grant Senhwa completed its NTD$ 198 million fundraising.

Feb.	CX-4945: The US FDA approves a phase I/II trial that used in Cholangiocarcinoma
Mar.	Senhwa and Development Center for Biotechnology (DCB) signed a Collaboration Agreement
Apr.	Senhwa qualified to regulations and investment incentives according to “Act For The Development Of Biotech And New Pharmaceuticals Industry” by Biotechnology and Pharmaceutical Industries Promotion Office, MOEA, Taiwan Senhwa’s clinical partner Peter MacCallum Cancer Centre (PMCC) was invited and presented the results of CX-5461 in animal study at AACR Annual Meeting 2014.
Aug.	Senhwa completed its NTD$ 27.6 million fundraising.
Sept.	Senhwa won the silver prize of 2014 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards.
Oct.	Senhwa completed its initial public offering of stock.
Dec.	Senhwa debuts on Taiwan's emerging stock market and begins trading under the ticker"6492.TT" on 4 Dec. 2014 An investigational new drug (IND) application was submitted to Korean Ministry of Food and Drug Safety (MFDS) for treatment of human Cholangiocarcinoma with CX-4945

Jan.	CX-4945: Senhwa receives Korean MFDS approval to begin Phase I/II trial for Cholangiocarcinoma.
Sept.	Senhwa and Chaperone Therapeutics, Inc. enter into an exclusive license agreement focused on the development of CK2 inhibitor for the treatment of neurodegenerative diseases. CX-5461 granted 2015 Canada SU2C-CBCF Dream Team Drug and funded for a total of CAD$ 9 Million over 4 years.
Oct.	CX-4945: Senhwa receives Taiwan FDA approval to begin Phase I/II trial for Cholangiocarcinoma.
Dec.	Senhwa’s clinical partner Peter MacCallum Cancer Centre (PMCC) published the study of CX-5461 combined with other drugs in treatment of Haematologic Malignancies in Clinical Cancer Research.

Mar.	Senhwa enters into Clinical Trial Agreement with Canadian Cancer Trials Group (CCTG) for CX-5461 Phase I/II Study. Health Canada approves Clinical Trial Application for Phase I/II Clinical Trial of CX-5461 in Solid Tumors and Breast Cancers.
Oct.	Senhwa filed an application with the Taiwan Stock Exchange to seek a primary listing on the main board.
Nov.	Senhwa filed a new patent application covering the use of CX-5461 in combination with PARP inhibitors, PI3K and immunotherapeutic agents. CX-5461 shows a synergistic effect in prostate cancer cells when combined with targeted drug, and this data was published by Senhwa’s partner in Australia.
Dec.	US subsidiary appointed Dr. Lucas S. Chang as General Counsel CX-4945 Phase I clinical trial results accepted for presentation at the 2017 ASCO Gastrointestinal Cancers Symposium CX-4945 granted Orphan Drug Designation by the US FDA in Cholangiocarcinoma

Jan.	Taipei Exchange board of directors approved listing application on the Exchange's Main Board
Feb.	US subsidiary promoted John Soong M.D., FCAP as Chief Medical Officer The research of CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours was accepted and published in Nature Communications on 17th
Mar.	Senhwa held pre-TPEx-listing performance presentation on 17th
Apr.	Senhwa raised NT$1.4 billion ($45.5 million) through the sale of 8.5 million shares at NT$162 in an IPO Senhwa completed IPO and began trading on the TPEx mainboard on 24th
Oct.	Registered Capital changed to NTD$743,456,200

Jan.	Registered Capital changed to NTD$743,926,200
Apr.	Registered Capital changed to NTD$744,166,200
May.	PBTC and Senhwa sign cooperation agreement to develop CX-4945 for pediatric brain tumor treatment

FULLOW US